Susan Serrao

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients

News /

MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative diseases. Building upon intellectual property licensed from Harvard Medical School, BioAegis believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), should be considered as a viable therapeutic […]

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients Read More »

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast

News /

Our Chief Medical Officer and infectious disease expert, Dr. Mark DiNubile, was recently interviewed for a KYW InDepth podcast. Highlights of the podcast include:  What happens to our lungs when COVID-19 attacks our bodies and why some people end up in the ICU on ventilators. How the naturally-occurring human protein, plasma gelsolin, works in our

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast Read More »

Plasma Gelsolin to Protect Tissue/Organs in Severe Coronavirus Infection without Compromising Pathogen Response

COVID19 /

SUMMARY SARS-CoV-2 causes fatal infections by eliciting an over-exuberant immune response leading to injurious lung inflammation +/- a cytokine storm.  Patients may die from ARDS or survive with debilitating pulmonary fibrosis.  Interventions like hydroxychloroquine have been proposed as treatment modalities to modulate the intense host reaction and potentially improve respiratory outcomes despite lack of a

Plasma Gelsolin to Protect Tissue/Organs in Severe Coronavirus Infection without Compromising Pathogen Response Read More »

February, 2020: BioAegis Commentary Featured on CNBC

News /

Commentary Steve Cordovano, co-founder of BioAegis Therapeutics Published February 25, 2020 On Tuesday the number of confirmed coronavirus cases worldwide hit 80,370, with more than 2,700 deaths worldwide, raising concerns that the outbreak has reached a new stage and could continue its global spread. But why is it that the health sector is so woefully unprepared

February, 2020: BioAegis Commentary Featured on CNBC Read More »

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman

News /

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman Read More »